LP
CGEM icon

Longaeva Partners’s Cullinan Oncology CGEM Stock Holding History

Longaeva Partners’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Sell
64,785
-118,906
-65% -$1.77M 0.03% 287
2026
Q1 		$2.61M Buy
+183,691
New +$2.36M 0.1% 140

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Longaeva Partners's CGEM Position: Q2 2026 in Review

Longaeva Partners reduced its Cullinan Oncology (CGEM) stake by 65% in Q2 2026, selling an estimated $1.77M and leaving 64,785 shares worth $1.18M. The position accounts for 0.03% of the portfolio, ranked #287.

Longaeva Partners first reported a position in CGEM in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.61M in Q1 2026. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Longaeva Partners held 64,785 shares of Cullinan Oncology worth $1.18M as of Q2 2026.
  • Longaeva Partners sold 118,906 Cullinan Oncology shares in Q2 2026, an estimated $1.77M.
  • Cullinan Oncology made up 0.03% of Longaeva Partners's portfolio in Q2 2026, its #287 holding.
  • Longaeva Partners first reported a position in Cullinan Oncology in Q1 2026 and has held it in 2 quarters since.
  • Longaeva Partners's Cullinan Oncology position peaked at $2.61M in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.